Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment

Mohamed Abou-El-Enein, Toni Cathomen, Zoltán Ivics, Carl H. June, Matthias Renner, Christian K. Schneider, Gerhard Bauer

Research output: Contribution to journalComment/debatepeer-review

15 Scopus citations

Abstract

As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues. As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.

Original languageEnglish (US)
Pages (from-to)427-430
Number of pages4
JournalCell Stem Cell
Volume21
Issue number4
DOIs
StatePublished - Oct 5 2017

Keywords

  • benefit-risk assessment
  • clinical trials
  • efficacy
  • genome editing
  • off-target effects
  • regulations
  • safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Fingerprint Dive into the research topics of 'Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment'. Together they form a unique fingerprint.

Cite this